BofA downgrades Zoetis (ZTS) to neutral, cuts price target
I'm PortAI, I can summarize articles.
BofA has downgraded Zoetis Inc. (NYSE:ZTS) from Buy to Neutral and reduced its price target from $165 to $135. Despite this downgrade, Zoetis is still listed among the 14 Best Pharma Dividend Stocks to Buy in 2026. Additionally, on December 5, Zoetis received Health Canada approval for Portela™ (relfovetmab injection).
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments